Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: Changes that are partially reversed by non-steroidal anti-inflammatory drugs usage

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 7, 2004, Pages 793-802

  Amano, Y ^a   Ishihara, S ^b   Kushiyama, Y ^b   Yuki, T ^b   Takahashi, Y ^b   Chinuki, D ^b   Miyake, T ^a   Miyaoka, Y ^b   Rumi, M A K ^b   Ishimura, N ^b   Adachi, K ^b   Kinoshita, Y ^b  

^a SHIMANE UNIVERSITY HOSPITAL   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; LOXOPROFEN; MELOXICAM; MUCIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; EPITHELIUM CELL; ESOPHAGUS BIOPSY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BARRETT ESOPHAGUS; BIOPSY; CELL PROLIFERATION; CHRONIC DISEASE; CYCLOOXYGENASE 2; ESOPHAGUS; FEMALE; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; METAPLASIA; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 4844225638     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02195.x     Document Type: Article

References (42)

1. Cameron AI, Zinsmeister AR, Ballard DI, et al. Prevalence of columnar-lined (Barrett's) esophagus. Gastroenterology 1990; 99: 918-22.
2. Blot WJ, Devessa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-89.
3. Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-13.
4. Endo T, Asakawa T, Takahashi H, et al. Classification of Barrett's epithelium by magnifying endoscopy. Gastrointest Endosc 2002; 55: 641-47.
5. Van De Bovenkamp JH, Korteland-Van Male AM, Warson C, et al. Gastric-type mucin and TFF-peptide expression in Barrett's oesophagus is disturbed during increased expression of MUC2. Histopathology 2003; 42: 555-65.
6. Arul GS, Moorghen M, Myerscough N, et al. Mucin gene expression in Barrett's oesophagus: an in situ hybridization and immunohistochemical study. Gut 2000; 47: 753-61.
7. Warson C, Van De Bovenkamp JH, Korteland-Van Male AM, et al. Barrett's esophagus is characterized by expression of gastric-type mucins (MUC5AC, MUC6) and TFF peptides (TFF1 and TFF2), but the risk of carcinoma development may be indicated by the intestinal-type mucin, MUC2. Hum Pathol 2002; 33: 660-68.
8. Guillem P, Billeret V, Buisine MP, et al. Mucin expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer 2000; 88: 856-61.
9. Chinyama CN, Marshall RE, Owen WJ, et al. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation. Histopathology 1999; 35: 517-24.
10. Fosslien E. Review: Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 2001; 31: 325-48.
11. Bishop-Bailey D, Calatayud S, Warner TD, et al. Prostaglandins and the regulation of tumor growth. J Environ Pathol Toxicol Oncol 2002; 21: 93-101.
12. Michael MS, Badr MZ, Badawi AF. Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells. Int J Mol Med 2003; 11: 733-36.
13. Morris CD, Armstrong GR, Bigley G, et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001; 96: 990-96.
14. Kaur BS, Triadafilopoulos G. Acid- and bile-induced PGE2 release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-ε dependent. Am J Physiol Gastrointest Liver Physiol 2002; 283: G327-34.
15. Kandil HM, Tanner G, Smalley W, et al. Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci 2001; 46: 785-89.
16. Zhang W, Wang L, Chang A, et al. Immunohistochemical analysis of cyclooxygenase-2 expression in premalignant and malignant esophageal glandular and squamous lesions in Cixian, China. Cancer Detect Prev 2003; 27: 243-49.
17. Lagorce C, Paraf F, Vidaud D, et al. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Histopathology 2003; 42: 457-65.
18. Cheong E, Igali L, Harvey I, et al. Cyclo-oxygenase-2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study. Aliment Pharmacol Ther 2003; 17: 379-86.
19. Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthetase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinoma. Cancer Res 1998; 58: 2929-34.
20. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
21. Amano K, Adachi K, Katsube T, et al. Role of hiatus hearnia and gastric mucosal atrophy in the development of reflux esophagitis in the elderly. J Gastroenterol Hepatol 2001; 16: 132-36.
22. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The practice parameters committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 1028-32.
23. Bara I, Loisillier F, Burtin P. Antigens of gastric and intestinal mucous cells in human colonic tumours. Br J Cancer 1980; 41: 209-21.
24. Bara J, Gautier R, Mouradian P, et al. Oncofetal mucin M1 epitope family: characterization and expression during colonic carcinogenesis. Int J Cancer 1991; 47: 304-10.
25. Ho SB, Niehans GA, Lyftogt C, et al. Heterogenicity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993; 53: 641-51.
26. Weiss AA, Babyatsky MW, Ogata S, et al. Expression of MUC2 and MUC3 mRNA in human normal, malignant, and inflammatory intestinal tissues. J Histochem Cytochem 1996; 44: 1161-66.
27. Flucke U, Steinborn E, Dries V, et al. Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach. Histopathology 2003; 43: 127-34.
28. Nollet S, Escande F, Buisine MP, et al. Mapping of SOMU1 and M1 epitopes on the apomucin encoded by the 5′ end of the MUC5AC gene. Hybrid Hybridomics 2004; 23: 93-9.
29. Buskens CJ, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002; 122: 1800-807.
30. Jang TJ, Min SK, Bae JD, et al. Expression of cyclooxygenase 2, microsomal prostaglandin E synthase 1, and EP receptors is increased in rat oesophageal squamous cell dysplasia and Barrett's metaplasia induced by duodenal contents reflux. Gut 2004; 53: 27-33.
31. Zimmermann KC, Sarbia M, Weber A, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198-204.
32. Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118: 487-96.
33. Fujii T, Nakagawa S, Hanzawa M, et al. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus. Oncol Rep 2003; 10: 427-31.
34. Kaur BS, Khamnehei N, Iravani M, et al. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002; 123: 60-7.
35. van der Woude CJ, Jansen PL, Tiebosch AT, et al. Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype. Hum Pathol 2002; 33: 686-92.
36. Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002; 122: 1101-12.
37. Fennerty MB. Does chemoprevention of Barrett's esophagus using acid suppression and/or COX-2 inhibition prevent neoplastic progression? Rev Gastroenterol Disord 2002; 2 (Suppl. 2): S30-7.
38. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995; 76: 1116-19.
39. Farrow DC, Vaughan TL, Hauten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 97-102.
40. Langman MJ, Cheng KK, Gilman EA, et al. Effect of antiinflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000; 320: 1642-46.
41. Souza RF, Shewmake K, Beer DG, et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000; 60: 5767-72.
42. Buttar NS, Wang KK, Anderson MA, et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. JNCI 2002; 94: 422-29.